Abstract:
There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder.
Abstract:
There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder.
Abstract:
The front-end integrated circuit includes a first clock unit receiving a reference clock signal from an oscillator and generating a first clock signal, a first analog front end module receiving and processing a first broadcast signal using the first clock signal, a second clock unit receiving the reference clock signal and generating a second clock signal, and a second analog front end module receiving and processing a second broadcast signal using the second clock signal.
Abstract:
Described embodiments provide a method of a circuit switched (CS) fallback procedure at a first network providing only a packet switched (PS) service. A CS fallback procedure may be initiated upon a receipt of a call associated with a CS service. One of carriers assigned to a second network that provides a circuit switched (CS) service may be selected. Then, a second network cell mapped to a serving cell of the first network and using the selected carrier may be selected as a target cell. The user equipment may be handed over o to the selected second network cell in order to provide a requested CS service.
Abstract:
The disclosure is related to controlling an operation bandwidth for a femtocell based on femtocell interference to a macrocell in order to minimize femtocell interference. A femtocell base station may include a measurement unit, a transmitting unit, and a control unit. The measurement unit may be configured to measure an interference amount of a macrocell adjacent to the femtocell base station. The transmitting unit may be configured to transmit the measured interference amount to a system. The control unit may be configured to i) accept an allocated operation bandwidth by the system and ii) control transmission and reception of signals with the allocated operation bandwidth. The operation bandwidth may be adjustable by the system based on the measured interference amount.
Abstract:
The disclosure is related to measuring macrocell quality of a macrocell using femtocells. A method may be provided for measuring macrocell quality of at least one macrocell using a femtocell base station. The method may include measuring, by the femtocell base station, macrocell quality of at least one macrocell based on event information, generating macrocell quality report information based on a result of the measuring, and transmitting the generated macrocell quality report information to a server through a femtocell gateway. The measuring macrocell quality may include determining whether a macrocell identifier is present in the event information, measuring the macrocell quality of a target macrocell corresponding to the mermen identifier of the event when the macrocell identifier is present in the event information, and measuring the macrocell quality of substantially all neighbor macrocells when the macrocell identifier is absent from the event information.
Abstract:
There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder
Abstract:
Provided is a method for automatically setting an area code by a femto access point (AP) located in a coverage area of a macro cell. The method includes receiving a broadcast signal of the macro cell, extracting an area code of the macro cell from the received broadcast signal, and setting the extracted area code as an area code of the femto cell. The femto AP sets the same area code as that of the macro cell as its area code and transmits the area code of the femto AP to the mobile station, thereby preventing the mobile station from repeating the location registration and enabling the mobile station to receive the same paging message from the femto AP and the macro cell.
Abstract:
A system and method for handoff in an integrated cell. A user equipment selects an integrated cell as a target cell supporting a target network based on a white list and physical cell identities. A cell-to-cell handoff is performed to the target cell. After the cell-to-cell handoff, a base station of the target cell establishes a communication session directly to a service. Then, the user equipment determines whether or not a physical cell identity of a base station of the target cell is an integrated physical cell identity. The user equipment turns on a module for the target network when the physical cell identity of the base station is determined to be the integrated physical cell identity. A heterogeneous-network handoff is then performed, and the base station communicates directly with a service server using a mapping table in order to seamlessly provide the service to the user equipment.
Abstract:
There is provided a novel carbamoyloxy arylalkanoyl arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the Formula 1, and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound, and a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof.